Esmolol is a beta-adrenergic blocker indicated for the short-term treatment of control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia, among other approved uses. MedsAcross supplies Esmolol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia. • Control of perioperative tachycardia and hypertension
Source: US FDA prescribing information
BREVIBLOC (Esmolol Hydrochloride) injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. BREVIBLOC injection inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature.
Source: US FDA prescribing information
• Administer intravenously. • Titrate using ventricular rate or blood pressure at ≥4-minute intervals. • Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia. • Optional loading dose: 500 mcg per kg infused over one minute • Then 50 mcg per kg per minute for the next 4 minutes • Adjust dose as needed to a maximum of 200 mcg per kg per minute. • Additional loading doses may be administered • Perioperative tachycardia and hypertension. • Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control) • Then 50 mcg per kg per min for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per min
Source: US FDA prescribing information
BREVIBLOC (Esmolol Hydrochloride) injection is contraindicated in patients with: • Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest. • Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest. • Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest. • Decompensated heart failure: May worsen heart failure. • Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.
Source: US FDA prescribing information
• Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use. • Risk of exacerbating reactive airway disease. • Diabetes: May mask symptoms of hypoglycemia and alter glucose levels, monitor. • Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma. • Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease
Source: US FDA prescribing information
Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension
Source: US FDA prescribing information
Concomitant use of BREVIBLOC injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate BREVIBLOC injection’s effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects.
Source: US FDA prescribing information
Protect from freezing. Storage Store at 25˚C (77˚F). Excursions permitted to 15˚-30˚C (59˚-86˚F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Esmolol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Esmolol 100 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Esmolol 2500 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Esmolol 2000 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Brevibloc 100 mg/10 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Brevibloc 2000 mg/100 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Brevibloc 2500 mg/250 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 31 December 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Esmolol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Esmolol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Esmolol, including Brevibloc.
Yes. The US FDA first approved Esmolol on 31 December 1986, according to Drugs@FDA.
No listed presentation of Esmolol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Esmolol is classified under ATC code C07AB09 (Esmolol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.